Observational studyMedicine2019
Risk factors for lymph node metastasis in duodenal neuroendocrine tumors: A retrospective, single-center study.
Observational study in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Nodal metastasis from an occult duodenal gastrinoma amid an overlap of xanthogranulomatous and type 1 autoimmune pancreatitis: A case report.Radiology case reports · 2026Article
- Nonexposure full-thickness resection in a laparoscopic-endoscopic approach as a hybrid technique for nonampullary duodenal neuroendocrine tumor.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2025Article
- Long-Term Outcomes in Patients With Non-Ampullary Duodenal Neuroendocrine Tumors.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- How Should Incidentally Detected Non-Ampullary Duodenal Neuroendocrine Tumors Be Treated?The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Long-term outcomes of endoscopic resection for duodenal neuroendocrine tumors.Scientific reports · 2023Article
- Diagnostic features and management options for duodenal neuroendocrine neoplasms: a retrospective, multi-centre study.Scientific reports · 2022Article
- Risk factors for lymph node metastasis and indication of local resection in duodenal neuroendocrine tumors.JGH open : an open access journal of gastroenterology and hepatology · 2022Article
- The Role of Endoscopy in Small Bowel Neuroendocrine Tumors.Clinical endoscopy · 2021Review
- Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy.Journal of endocrinological investigation · 2021Article
- Giant retroperitoneal lymph node-an uncommon presentation of duodenal neuroendocrine tumour.BMJ case reports · 2021Article
- A subcentimeter duodenal neuroendocrine neoplasm with a liver metastasis upgraded to G3: a case report.Surgical case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Duodenal neuroendocrine tumors (NETs) are rare, and risk factors associated with lymph node (LN) metastasis are still not well defined. The aim of this study was to investigate risk factors of LN metastasis in duodenal NETs based on the final histopathologic results and clinical follow-up data.This study included a total of 44 duodenal NETs in 38 patients who underwent endoscopic or surgical resection between January 2008 and December 2015. Diagnosis of duodenal NETs was confirmed based on immunohistochemical staining of chromogranin A, synaptophysin, and CD56; the clinicopathologic records were collected at the time of the initial diagnosis of duodenal NETs.Most duodenal NETs were small (≤1 cm in 33 tumors), World Health Organization (WHO) grade G1 (in 32 tumors), limited to the mucosa and/or submucosa (in 40 tumors), and located at the duodenal bulb (in 32 tumors). Of 44 tumors, lymphovascular invasion was present in 4 (9.1%), and among 38 patients, LN metastasis was detected in 4 (10.5%). LN metastases were significantly associated with the non-bulb location, tumor size >10 mm, tumor invasion into the muscularis propria or deeper, WHO grade G2, and lymphovascular invasion. During the mean follow-up period of 54.5 months (range, 24-123 months), recurrence occurred in 1 patient.Non-bulb location, tumor size >10 mm, invasion beyond the submucosa, WHO grade G2, and lymphovascular invasion are risk factors of LN metastasis in duodenal NETs. These findings can help clinicians choose the appropriate therapeutic modality for duodenal NETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.